Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicaid Reform Next On Health Care Agenda: GAO To Assess Rebates

Executive Summary

The House Energy & Commerce/Oversight Subcommittee is directing the General Accounting Office to review Medicaid reimbursement policies in preparation for debate over reforms to the program

You may also be interested in...



Medicare Payments Still “Excessive” For Albuterol And Ipatropium, IG Says

The HHS Inspector General is recommending significant further cuts in reimbursement for albuterol and ipatropium bromide under Medicare Part B

Medicaid Directors May Seek Clarification On Rebates In Medicare Rx

The National Association of State Medicaid Directors is hoping for clarification that Medicaid rebates will be factored into "clawback" payments made by states for coverage of dual eligibles under the new Medicare drug benefit

Oncology Rx Pricing Focus Shifts To Medicaid: House Cmte. Seeks Documents

The passage of AWP reform in Medicare will not end Congressional scrutiny of the oncologic drug market

Related Content

UsernamePublicRestriction

Register

PS043309

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel